Formycon AG FYB.F Stock
Formycon AG Price Chart
Formycon AG FYB.F Financial and Trading Overview
| Formycon AG stock price | 50 EUR |
| Previous Close | 67.4 EUR |
| Open | 67.5 EUR |
| Bid | 67.5 EUR x 30000 |
| Ask | 0 EUR x 30000 |
| Day's Range | 67.4 - 67.4 EUR |
| 52 Week Range | 64.1 - 91.7 EUR |
| Volume | 100 EUR |
| Avg. Volume | 180 EUR |
| Market Cap | 1.08B EUR |
| Beta (5Y Monthly) | 0.95977 |
| PE Ratio (TTM) | 26.431374 |
| EPS (TTM) | 4.72 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54.75 EUR |
FYB.F Valuation Measures
| Enterprise Value | 1.07B EUR |
| Trailing P/E | 26.431374 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 25.437447 |
| Price/Book (mrq) | 2.8595674 |
| Enterprise Value/Revenue | 25.173 |
| Enterprise Value/EBITDA | -62.846 |
Trading Information
Formycon AG Stock Price History
| Beta (5Y Monthly) | 0.95977 |
| 52-Week Change | -6.32% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 91.7 EUR |
| 52 Week Low | 64.1 EUR |
| 50-Day Moving Average | 70.25 EUR |
| 200-Day Moving Average | 76.08 EUR |
FYB.F Share Statistics
| Avg. Volume (3 month) | 180 EUR |
| Avg. Daily Volume (10-Days) | 45 EUR |
| Shares Outstanding | 16.04M |
| Float | 10.08M |
| Short Ratio | N/A |
| % Held by Insiders | 51.77% |
| % Held by Institutions | 9.04% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 84.69% |
| Operating Margin (ttm) | -41.71% |
| Gross Margin | 28.40% |
| EBITDA Margin | -40.054% |
Management Effectiveness
| Return on Assets (ttm) | -2.39% |
| Return on Equity (ttm) | 17.45% |
Income Statement
| Revenue (ttm) | 42.5M EUR |
| Revenue Per Share (ttm) | 3.1 EUR |
| Quarterly Revenue Growth (yoy) | 50.50% |
| Gross Profit (ttm) | N/A |
| EBITDA | -17022000 EUR |
| Net Income Avi to Common (ttm) | 35.99M EUR |
| Diluted EPS (ttm) | 2.55 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 9.82M EUR |
| Total Cash Per Share (mrq) | 0.65 EUR |
| Total Debt (mrq) | 49.31M EUR |
| Total Debt/Equity (mrq) | 13.83 EUR |
| Current Ratio (mrq) | 0.602 |
| Book Value Per Share (mrq) | 23.57 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -18878000 EUR |
| Levered Free Cash Flow (ttm) | -23878124 EUR |
Profile of Formycon AG
| Country | Germany |
| State | N/A |
| City | Planegg |
| Address | Fraunhoferstrasse 15 |
| ZIP | 82152 |
| Phone | 49 89 864 667 100 |
| Website | https://www.formycon.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 137 |
Formycon AG develops and markets biosimilar products in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema and myopic choroidal neovascularization under the Ranivisio, ONGAVIA, and CIMERLI names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of chronic inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea, that treats neovascular age-related macular degeneration and serious retinal diseases that is in Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of cancer; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Q&A For Formycon AG Stock
What is a current FYB.F stock price?
Formycon AG FYB.F stock price today per share is 50 EUR.
How to purchase Formycon AG stock?
You can buy FYB.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Formycon AG?
The stock symbol or ticker of Formycon AG is FYB.F.
Which industry does the Formycon AG company belong to?
The Formycon AG industry is Biotechnology.
How many shares does Formycon AG have in circulation?
The max supply of Formycon AG shares is 18.47M.
What is Formycon AG Price to Earnings Ratio (PE Ratio)?
Formycon AG PE Ratio is 10.59322100 now.
What was Formycon AG earnings per share over the trailing 12 months (TTM)?
Formycon AG EPS is 4.72 EUR over the trailing 12 months.
Which sector does the Formycon AG company belong to?
The Formycon AG sector is Healthcare.